Media stories about Innospec (NASDAQ:IOSP) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innospec earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave press coverage about the specialty chemicals company an impact score of 45.9204445154557 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
IOSP has been the subject of several research analyst reports. Johnson Rice raised shares of Innospec from a “hold” rating to an “accumulate” rating in a report on Tuesday, November 14th. Zacks Investment Research raised shares of Innospec from a “hold” rating to a “buy” rating and set a $76.00 price target for the company in a report on Friday, November 10th. ValuEngine raised shares of Innospec from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. BidaskClub raised shares of Innospec from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Finally, Monness Crespi & Hardt downgraded shares of Innospec from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $70.50.
Shares of Innospec (NASDAQ IOSP) opened at $71.20 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.35 and a current ratio of 2.24. The stock has a market capitalization of $1,720.00, a PE ratio of 19.67 and a beta of 1.21. Innospec has a twelve month low of $54.10 and a twelve month high of $74.75.
Innospec (NASDAQ:IOSP) last issued its earnings results on Tuesday, November 7th. The specialty chemicals company reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.15. The company had revenue of $332.40 million for the quarter, compared to the consensus estimate of $309.40 million. Innospec had a return on equity of 15.05% and a net margin of 7.45%. The firm’s quarterly revenue was up 61.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 EPS. equities analysts expect that Innospec will post 4.3 earnings per share for the current year.
In related news, VP Brian Watt sold 440 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $70.17, for a total value of $30,874.80. Following the completion of the sale, the vice president now owns 30,730 shares of the company’s stock, valued at approximately $2,156,324.10. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Patrick Williams sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $71.49, for a total value of $1,072,350.00. Following the completion of the sale, the chief executive officer now directly owns 174,242 shares of the company’s stock, valued at approximately $12,456,560.58. The disclosure for this sale can be found here. Insiders sold a total of 24,366 shares of company stock worth $1,743,891 in the last quarter. 2.02% of the stock is owned by corporate insiders.
Innospec Inc is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives.
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.